A Phase 3 interventional study of Sulodexide and Sulodexide and placebo in Venous Thromboembolism, Anticoagulant and Elderly, sponsored by Arianna Anticoagulazione Foundation. Recruiting at 1 site in Italy. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2024-07-31.
Sponsored by Arianna Anticoagulazione Foundation · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Venous Thromboembolism with a site in Italy — 10 open to participants now, 13 under way, 3 of them phase 3. Venous Thromboembolism · Italy.
Among the 74 studies in Venous Thromboembolism with a site in Italy, this one is the 17th largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2020, is one of 32 in phase 3, reaches primary completion later than 3 of the 12 other live ones, and was the 60th registered.
714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.
Browse Venous Thromboembolism studies →10 of the 74 studies in Venous Thromboembolism with a site in Italy are open now. Recruiting first, the newest first:
Azienda Ospedaliero-Universitaria Careggi · Sites in Italy, Poland, Spain
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
University Of Perugia · Sites in Italy
Ages 18+
Ottawa Hospital Research Institute · Sites in Italy, Canada, France and 3 more countries
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Italy, Netherlands, Spain
Ages 18–120
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 75 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 34 · Phase 4 4
First in 1998; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,455 is above the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 839 across the 50 interventional studies, 2,040 across the 23 observational. Of the 58 that completed or were terminated, 23 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 74 have an industry lead sponsor. The 10 most frequent:
Arianna Anticoagulazione Foundation is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Arianna Anticoagulazione Foundation has 3 studies filed under Venous Thromboembolism — fewer than ten, so there is no comparison to draw.
2 of the studies in Venous Thromboembolism with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07228663Phase 3McMaster UniversityHip Fracture Surgery Arterial and Venous Thrombotic Events Prevention | 2027-07-01 |
| NCT02832245Manuel MonrealComputerized Registry of Patients With Venous Thromboembolism (RIETE) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 74 studies in Venous Thromboembolism with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients were randomized to receive three different treatment: Sulodexide 250 mg BIS in die; Sulodexide 500 BID in die or indistinguishable placebo to verify the efficacy and safety of extended treatment for 12 months with Sulodexide (Vessel®) in the secondary prevention of Deep Vein Thrombosis / Pulmonary Embolism (DVT/PE) recurrence.
This prospective cohort study aims to assess the efficacy and safety of the extended treatment with Sulodexide (Vessel®) in the secondary prevention of DVT / PE recurrence in elderly outpatients (≥ 75 years old at the time of inclusion) ), with at least one of the known bleeding risk factor, who had a first episode of lower extremity proximal DVT and / or PE, idiopathic or associated with weak or removed risk factors, and who have received standard treatment with any oral anticoagulant drug lasting at least 3 months. The study seeks to verify the safety of the Sulodexide therapy, demonstrating non-inferiority compared to placebo, with an incidence of major bleeding around 1% (upper confidence limit not > 3%).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with at least one of the known risk factors of bleeding (APPENDIX 1):
Exclusion Criteria:
"Provoked" index event, which occurred:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sulodexide (Vessel) 2 capsules of 250 LSU BID, for 12 months
Drug: Sulodexide
Sulodexide (Vessel) 1 capsule of 250 LSU and 1 indistinguishable placebo capsule BID., for 12 months
Drug: Sulodexide and placebo · Drug: Placebo
2 indistinguishable placebo capsules BID, for 12 months
Drug: Placebo
2 soft capsules of Vessel® 250 LSU BID for 12 months
Also known as: VESSEL®
1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months
Also known as: VESSEL® and placebo
Sugar pill manufactured to mimic sulodexide 250 LSU
Also known as: 2 soft capsule of placebo BDI for 12 months
Number and rate of patients with confirmed recurrent VTE and VTE-related death (efficacy).
The occurrence of proximal deep vein thrombosis with or without pulmonary embolism (new or recurrent episode) wil be recorded in all patients
Time frame: From date of enrollment until the date of first documented event assessed up to 12 months
Number and rate of major Bleeding events (defined according to International Society on Thrombosis and Haemostasis guidelines (safety)
Fatal bleeding; intracranial; intraspinal; intraocular; pericardial; intra-articular; intramuscular with compartment syndrome; retroperitoneal,; acute clinically overt bleeding will be recorded in all patients
Time frame: From date of enrollment until the date of first documented event assessed up to 12 months
Number of and rate of thromboembolic events
Transient ischemic attack (TIA), Stroke, Myocardial infarction will be recorded in all patients
Time frame: From date of enrollment until the date of first documented event assessed up to 12 months
Presence of severe post-thrombotic syndrome according to Villalta Score
Patient with deep vein thrombosis as index event will be evaluated, at the and of follow-up, applying Villalta score, commonly used to diagnose post-thrombotic syndrome in the subacute phase of thrombosis. The presence of venous ulcer of the leg or a score \> of 15 points indicate the occurrence of severe post-thrombotic syndrome. The maximum score is 33. The score from 5 to 9 points indicate mild post-thrombotic syndrome and from 10 to 15 points indicate moderate post-thrombotic syndrome
Time frame: 12 months
Number and rate of non major bleeding complications
In all patients will be recorded any sign or symptom of hemorrhage that does not fit the criteria for the definition of major bleeding but does meet at least one of the following criteria: 1)requiring medical intervention by a healthcare professional; 2) leading to hospitalization or increased level of care;3) prompting a face to face evaluation
Time frame: From date of enrollment until the date of first documented event assessed up to 12 months
Number and rate of dead patients (overall mortality)
VTE-related death; cardiovascular related-death; bleeding-related death; death for: cancer, infectious disease and unknown cause; sudden death will be recorded in all patients
Time frame: From date of enrollment until the date of first documented event assessed up to 12 months
PDFs hosted by the registry, ClinicalTrials.gov.
Started Dec 2020 (actual). Primary completion is estimated for Dec 2025, 60 months after the start.
Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 60 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glucuronyl glucosamine glycan sulfate
Arianna Anticoagulazione Foundation